Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2435 • ACR Convergence 2023
Deciphering Rheumatoid Arthritis Disease Activity-Associated Gene Signatures and Cell Subsets Through Single Cell Transcriptomics
Marie Binvignat¹, Brenda Miao², Camilla Wibrand³, Monica Yang⁴, Dmitry Rychkov⁵, Emily Flynn⁴, Umair Khan⁴, Joanne Nititham⁶, Alex Carvidi⁴, Melissa Krueger⁴, Erene Niemi⁴, Yang Sun⁴, Gabriella Fragiadakis⁴, David Klatzmann¹, Jeremie SELLAM⁷, Encarnita Mariotti-Ferrandiz¹, Andrew Gross⁴, Chun Jimmie Ye⁴, Atul Butte⁴, Lindsey Criswell⁶, Mary Nakamura⁸ and Marina Sirota⁵, ¹Sorbonne Université, Paris, France, ²University of California San Francisco, Fremont, CA, ³Aarhus University, Aarhus, Denmark, and University of California San Francisco, San Francisco, CA, ⁴University of California San Francisco, San Francisco, CA, ⁵Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA, ⁶NIH/NHGRI, Bethesda, MD, ⁷Sorbonne Université APHP, Paris, France, ⁸UCSF/SFVAHCS, San Francisco, CA
Background/Purpose: Single cell transcriptional profiling (scRNA-Seq) is valuable in identifying gene signatures and cell subpopulations associated with rheumatoid arthritis (RA). However prior studies have often…
Abstract Number: 2509 • ACR Convergence 2023
Risk Factors and Mortality of Immune Checkpoint Inhibitor-Induced Flares of Pre-Existing Rheumatoid Arthritis: An Analysis Accounting for Competing Risk of Death and Immortal Time Bias
Kaitlin McCarter¹, Senada Arabelovic¹, Taylor Wolfgang¹, Xiaosong Wang¹, Kazuki Yoshida¹, Grace Qian¹, Emily Kowalski¹, Kathleen Vanni¹, Nicole LeBoeuf¹, Elizabeth Buchbinder², Lydia Gedmintas¹, Lindsey MacFarlane¹, Deepak Rao¹, Nancy Shadick³, Ellen Gravallese⁴ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Dana-Farber Cancer Institute, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Immune checkpoint inhibitors (ICI) stimulate the immune system to treat cancer but may cause flares of pre-existing immune-mediated inflammatory diseases. Risk factors for ICI-induced…
Abstract Number: PP06 • ACR Convergence 2023
Dana’s Data Dashboard: Applying a Familiar Framework for Efficient and Effective Health Management
Dana Guglielmo, Los Angeles, CA
Background/Purpose: As a researcher and data analyst, I enjoy the meticulous attention to detail that my work requires. I love the process of collecting, analyzing,…
Abstract Number: 0016 • ACR Convergence 2023
Role of TP53 in Inflammatory Reprogramming of Rheumatoid Arthritis Synovial Fibroblasts
Anil Singh and Salahuddin Ahmed, Washington State university, Spokane, WA
Background/Purpose: TP53, a tumor-suppressor protein known as the guardian of the genome, plays a critical role in regulating genomic stability and cellular function. When TP53…
Abstract Number: 0079 • ACR Convergence 2023
CD4 T Cell Repertoire Features in RA Patients with High-risk HLA-DRB1 Alleles
Amit Lakhanpal¹, Kazuyoshi Ishigaki², Anvita Singaraju¹, Alejandro Kochen³, Miriam Fein¹, Soumya Raychaudhuri⁴ and Laura Donlin¹, ¹Hospital for Special Surgery, New York, NY, ²RIKEN, Tokyo, Japan, ³Yale School of Medicine, New Haven, CT, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: A role for CD4 T cells in RA pathology is supported by the effectiveness of T cell therapies, genetic studies implicating T cell gene…
Abstract Number: 0217 • ACR Convergence 2023
Safety and Efficacy of Tixagevimab/Cilgavimab (Evusheld) in Autoimmune Inflammatory Rheumatic Disease Patients – a Prospective Multicenter Open-label Study
Tali Eviatar¹, Victoria Furer², Ilana Kaufman³, David levartovsky², Ofir Elalouf², Devy Zisman⁴, Tal Gazitt⁵, Amir Haddad⁴, Muna Elias⁶, Joy Feld⁷, Alexandra Balbir-Gurman⁸, Yolanda Braun Moscovici⁹, Sara Pel¹⁰, sharon Nevo¹¹, Daphna Paran² and Ori Elkayam², ¹Tel Aviv Sourasky Medical center, Ramat Gan, Israel, ²Tel Aviv Medical Center, Tel Aviv, Israel, ³Tel Aviv Medical Center, Petah-Tikva, Israel, ⁴Carmel Medical Center, Haifa, Israel, ⁵Carmel Hospital, Haifa, Israel, ⁶rheumatology unit, Haifa, Israel, ⁷Carmel and Zvulun Medical Centre, Haifa, Israel, ⁸Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ⁹Rambam Heath Care Campus, Haifa, Israel, ¹⁰Tel Aviv Medical Center, Modiin, Israel, ¹¹Tel Aviv Sourasky Medical Center, Givataim, Israel
Background/Purpose: Autoimmune inflammatory rheumatic disease (AIIRD) patients treated with rituximab (RTX) are at risk for severe COVID19 infection, and a blunted humoral response to SARS-CoV-2…
Abstract Number: 0383 • ACR Convergence 2023
Identification of Contributing Factors to Difficult-to-Treat Rheumatoid Arthritis (D2T RA) in a Cohort of 972 Patients Using a Natural Language Processing (NLP) Approach
Hugo BERGIER¹, Thibaut Fabacher², Nathanaël Sedmak², Erik Sauleau² and Jacques-Eric Gottenberg³, ¹Hautepierre Hospital, Strasbourg, France, ²Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ³Rheumatology Department, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Natural Language Processing (NLP), an interdisciplinary field combining artificial intelligence and language science, has gained significant interest in the medical domain for automated collection…
Abstract Number: 0399 • ACR Convergence 2023
Differential Synovial Tissue Enrichment of Oxylipins and Their Mediators Across Rheumatoid Arthritis Trajectory
Simone Perniola¹, Jessica Murillo-Saich², Barbara Tolusso³, Clara Di Mario³, Marco Gessi⁴, Dario Bruno⁵, Luca Petricca⁶, Maria Rita Gigante⁶, Elisa Gremese⁵, Monica Guma⁷ and Stefano Alivernini⁸, ¹Division of Clinical Immunology – Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ²Department of Medicine, University of California San Diego, La Jolla, CA, ³Immunology Research Core Facility – Gemelli Science and Technology Park (GSTeP) - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁴Division of Pathology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁵Division of Rheumatology, Institute of Rheumatology and Affine Sciences, School of Medicine, Catholic University of the Sacred Heart, Roma, Italy, ⁶Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁷University of California San Diego, La Jolla, CA, ⁸Immunology Research Core Facility, Gemelli Science and Technology Park, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy
Background/Purpose: Synovial membrane represents the target tissue of Rheumatoid Arthritis (RA) inflammation. Our study aimed to perform a comprehensive quantification of oxylipins and their precursors…
Abstract Number: 0416 • ACR Convergence 2023
Association Between Sleep Disorders and Rheumatoid Arthritis: A Population-based Cohort Study
Rakesh Kumar¹, Edward Lovering¹, Chanakya Kodishala², Sara Achenbach³, Diego Carvalho¹, Cynthia Crowson¹, John Davis¹ and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester Minnesota, Rochester, MN, ³Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: Some sleep disorders (SD) are more prevalent in patients with chronic inflammatory diseases, such as Rheumatoid Arthritis (RA). However, most of the research has…
Abstract Number: 0433 • ACR Convergence 2023
DMARD Initiation in Older Adults with New Diagnosis of Late-Onset Rheumatoid Arthritis
Jiha Lee¹, Jonathan Martindale¹, Una Makris², Namrata Singh³, Raymond Yung⁴ and Julie Bynum¹, ¹University of Michigan, Ann Arbor, MI, ²UT Southwestern Medical Center and Dallas VA, Dallas, TX, ³University of Washington, Bellevue, WA, ⁴Michigan Medicine, Ann Arbor, MI
Background/Purpose: The number of older adults living with rheumatoid arthritis (RA) is growing as the world population is aging. Up to one-third of the older…
Abstract Number: 0450 • ACR Convergence 2023
Baricitinib versus TNF-inhibitors in Patients with Active Rheumatoid Arthritis After Failure of CsDMARDs: A Pragmatic, Multicenter, Real-Life Study in a Treat-to-Target Setting
Martinus Van de Laar¹, Martijn Oude Voshaar¹, Peter ten Klooster¹, Danyta Tedjo² and celine van de laar³, ¹University of Twente, Hengelo (OV), Netherlands, ²TiH @ University of Twente, Hengelo (OV), Netherlands, ³Erasmus School of Health Policy and Management, Erasmus University, Rotterdam, Netherlands
Background/Purpose: The EULAR guidelines for Rheumatoid Arthritis (RA) patients advise to use a strategy aiming at a predefined target of disease activity (T2T). If this…
Abstract Number: 0583 • ACR Convergence 2023
Therapeutic Potential of Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, for the Treatment of Refractory Autoimmune Disease Patients
Racquel Domingo-Gonzalez¹, Isabelle Baribaud², Miho Oyasu¹, Sivani Pandey¹, Maya Leabman¹, Genevive Hernandez¹, Albert Candia¹, Stephen Carroll¹, Bruce Keyt¹, Maya Kotturi¹, Carrie Brodmerkel² and Mary Beth Harler², ¹IGM Biosciences, Inc., Mountain View, CA, ²IGM Biosciences, Inc., Doylestown, PA
Background/Purpose: B cell depletion therapy (BCDT) with conventional IgG antibodies (e.g.rituximab) has been used to treat autoimmune (AI) disease for several decades. However, many patients…
Abstract Number: 0774 • ACR Convergence 2023
Deciphering Rheumatoid Arthritis-associated Interstitial Lung Disease Phenotypes Using Unsupervised Hierarchical Clustering Analysis: Results from a Large Collaborative International Study
Pierre-Antoine Juge¹, Benjamin Granger², Lina El Houari³, Gregory McDermott⁴, Tracy J. Doyle⁴, Clive Kelly⁵, Gouri M Koduri⁶, Robert Vassallo⁷, Amarilys Alarcon Calderon⁷, Umut Kalyoncu⁸, Antonio Gonzalez⁹, Natalia Mena Vazquez¹⁰, Marta Rojas¹¹, Raquel Dos-Santos¹², Miriam Retuerto-Guerrero¹³, Cristina Vadillo-Font¹⁴, PALOMA VELA¹⁵, Antonio Fernandez-Nebro¹⁶, Alejandro Escudero-Contreras¹⁷, Eva Perez-Pampin¹⁸, Charlotte Hyldgaard¹⁹, Antoine Froidure²⁰, Patrick Durez²¹, Jorge Rojas Serrano²², Coline van Moorsel²³, Jan C Grutters²³, Leticia Kawano-Dourado²⁴, Charlotte Lucas²⁵, Stephane Jouneau²⁶, Raimon Sanmarti²⁷, Raul Castellanos Moreira²⁸, Katarina Antoniou²⁹, Maria Molina molina³⁰, joshua Solomon³¹, Sophia raia³¹, Miguel A Gonzalez-Gay³², Belén Atienza-Mateo³³, Sofia Flouda³⁴, Effrosyni Manali³⁴, Boumpas Dimitrios³⁵, Spyros Papiris³⁴, THEOFANIS KARAGEORGAS³⁶, Marco Sebastiani³⁷, Andreina Manfredi³⁸, Ana Catarina Duarte³⁹, Santos Castañeda⁴⁰, Lorenzo Cavagna⁴¹, Bruno Crestani⁴², Jeffrey Sparks⁴³ and Philippe Dieudé⁴⁴, ¹Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, ²Sorbonne Université, INSERM, and Pitié Salpêtrière Hospital, Paris, France, ³Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France, ⁴Brigham and Women's Hospital, Boston, MA, ⁵James Cook University Hospital, Middlesbrough, United Kingdom, ⁶Southend University Hospitals NHS Trust, Essex, United Kingdom, ⁷Mayo Clinic, Rochester, MN, ⁸Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁹Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ¹⁰IBIMA, Málaga, Spain, ¹¹Hospital Universitario Reina Sofía, Cordoba, Spain, ¹²Clinical University Hospital in Santiago de Compostela, Santiago de Compostela, Spain, ¹³Rheumatology, Hospital Universitario de León, León, Spain, ¹⁴Hospital Clínico San Carlos – Instituto Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ¹⁵Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ¹⁶Hospital Regional Universitario de Málaga, Malaga, Spain, ¹⁷Rheumatology Department, Reina Sofia University Hospital, Cordoba/Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Córdoba, Spain, ¹⁸Rheumatology Department Complejo Hospitalario Universitario Santiago, Santiago de compostela, Spain, ¹⁹Silkeborg Regional Hospital, Silkeborg, Denmark, ²⁰Université Catholique de Louvain, Louvain, Belgium, ²¹UCLouvain, Brussels, Belgium, ²²Hospital Angeles Villahermosa, Ciudad de Mexico, Mexico, ²³St. Antonius Hospital, Nieuwegein, Netherlands, ²⁴Hospital do Coração (HCor), São Paulo, Brazil, ²⁵CHU, Rennes, France, ²⁶Amicus, Boca Raton, FL, ²⁷Hospital Clinic, Rheumatology, Barcelona, Spain, ²⁸Hospital Clínic de Barcelona, Madrid, Spain, ²⁹University of Crete, Heraklion, Greece, ³⁰IDIBELL Bellvitge Biomedical Research Institute, Barcelona, Spain, ³¹National Jewish Health, Denver, CO, ³²IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ³³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁴Unit of Attikon University Hospital, Athens, Greece, ³⁵National and Kapodistrian University of Athens, Athens, Greece, ³⁶n/a, Athina, Greece, ³⁷Azienda Policlinico di Modena, Modena, Italy, ³⁸University of Modena, Modena, Italy, ³⁹Hospital Garcia de Orta, Almada, Portugal, ⁴⁰Hospital Universitario de la Princesa, Madrid, Spain, ⁴¹Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ⁴²Hopital Bichat, Paris University, Paris, France, ⁴³Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁴⁴Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, INSERM UMR1152, University de Paris Cité, Department of Rheumatology, Paris, France
Background/Purpose: RA-associated interstitial lung disease (ILD) is not a single entity as illustrated by different HRCT patterns, different risk factors and prognoses suggesting heterogenous phenotypes.…
Abstract Number: 0837 • ACR Convergence 2023
A Randomized, Double-Blind, Sham-Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis
Matthew Baker¹, Sarah Kavanagh², Stanley Cohen³, Alan Matsumoto⁴, Ara Dikranian⁵, John Tesser⁶, Alan Kivitz⁷, Konstantinos Alataris⁸ and Mark Genovese⁹, ¹Stanford University, Menlo Park, CA, ²Kavanagh Statistical Consulting, LLC, Apex, NC, ³Metroplex Clinical Research Center, Dallas, TX, ⁴Arthritis and Rheumatism Associates, Wheaton, MD, ⁵Cabrillo Center for Rheumatic Disease, San Diego, CA, ⁶Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁷Altoona Center for Clinical Research, Duncansville, PA, ⁸Nēsos, Menlo Park, CA, ⁹Stanford University, Sunnyvale, CA
Background/Purpose: Vagus nerve stimulation (VNS) has emerged in recent decades as a potential therapy for RA.We have previously shown that auricular VNS produced an average…
Abstract Number: 0985 • ACR Convergence 2023
Assessing the Value of Comorbidity Clusters in Predicting Clinical Outcomes in Rheumatoid Arthritis: A Machine Learning Approach Using a Very Large US Registry
Daniel Solomon¹, Fredrik Johansson², Hongshu Guan³, Leah Santacroce⁴, Lin Guo⁵, Wendi Malley⁵ and Heather Litman⁵, ¹Brigham and Women's Hospital, Newton, MA, ²Chalmers University of Technology, Goteborg, Sweden, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵CorEvitas, LLC, Waltham, MA
Background/Purpose: Comorbid conditions are very common in rheumatoid arthritis (RA) and several prior studies have derived comorbidity clusters using machine learning (ML). Clustering using ML…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].